Comparison 5. Subcutaneous omalizumab + steroid versus placebo + steroid (trial extension).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of participants achieving complete inhaled steroid withdrawal	1		Odds Ratio (M‐H, Fixed, 95% CI)	Totals not selected
1.1 Moderate to severe	1		Odds Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.2 Severe	0		Odds Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 Participants with one or more exacerbation	1		Odds Ratio (M‐H, Fixed, 95% CI)	Totals not selected
2.1 Moderate to severe asthma	1		Odds Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.2 Severe asthma	0		Odds Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3 Hospitalisations	1		Odds Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3.1 Moderate to severe asthma	1		Odds Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.2 Severe asthma	0		Odds Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4 Number of participants with any adverse event	1		Odds Ratio (M‐H, Fixed, 95% CI)	Subtotals only
4.1 Moderate to severe asthma	1	546	Odds Ratio (M‐H, Fixed, 95% CI)	0.88 [0.55, 1.39]
4.2 Severe asthma	0	0	Odds Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]